Expression Of IL-17, VEGF And ?2-MG In Patients With Multiple Myeloma Of Different Stages

Objective There are different treatment programs for Multiple myeloma(MM) patients by stages, so correct stagings of patients are of great significance for the treatment in later period. VEGF can promote tumor angiogenesis and plays an important role in the progress of the disease. IL- 17 is a powerful proinflammatory factor which can induce the expression of various inflammatory factors, activation of osteoclasts and inhibit the activity of osteoblast, accelerate the growth of myeloma cells. The ?2-MG can be a manifestation of tumor load of the body and is associated with patient survival. In order to explore the role of VEGF, IL- 17 and ? 2-MG in MM furtherly.We detect the the expression of IL- 17, VEGF and ?2-MG in serums of MM patients in different stages and healthy controls, then analyze the expression of three indicators and their relationship with the progression of disease.Methods and material53 cases of MM patients and 20 cases of healthy controls were selected. The 53 cases of MM patients were in patients who were confirmed as MM patients in the Department of Hematology of Henan Provincial People's Hospital from January 2015 to September 2015 and the 20 healthy adults are out patients who came to r the Henan Provincial People's Hospital for normal physical examination. Serum levels of IL-17 and VEGF were measured by enzyme-linked immunosorbent assay(ELISA). Serum levels of ? 2-MG were measured by Roche automated biochemical analyzer. The sera of the group of MM patients were measured for their serum protein electrophoresis.Results The expression of IL-17, VEGF and ?2-MG levels in MM patients are significantly higher than healthy controls(P < 0.05).While dividing the MM patients into ?, ?,? period according to the ISS stage, the expression level of IL-17, VEGF and ?2-MG in the phase ?of MM patients are significantly higher than that of phase?(P < 0.05); the expression level of IL-17, VEGF and ?2-MG in phase?are significantly higher than that in phase?(P < 0.05), the serum IL-17 expression has appositive correlation with the expression of ?2-MG and VEGF in MM patients respectively(r=0.647, P<0.05; r=0.667, P<0.05). The expression level of IL-17,VEGF, ?2- MG were positively correlated with the amount of M protein in MM patients.According to the international myeloma working group' indicators of treatment efficacy,we divided the experimental MM patients into two groups including active phase group patients and stable phase group patients.Both groups were compared with the healthy control group.We detected and analyzed the expression levels of serum IL-17, VEGF and ?2-MG.We found that the expression levels of IL-17?VEGF and ?2-MG were significantly higher in the serum of active patients than those of patients with stable MM(P <0.05). The expression levels of IL-17, VEGF and?2-MG in patients with stable MM were significantly higher than those in the control group(P <0.05).Conclusion(1) The expression level of IL-17, VEGF and ?2-MG are significantly higher in MM patients and relate to international myeloma working group' indicators of treatment efficacy and ISS stage of the disease significantly.(2)Detecting the expression of IL-17 and VEGF quantitatively may be of great significance in the progression and prognosis of multiple myeloma.